Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-24-079255
Filing Date
2024-07-11
Accepted
2024-07-11 17:01:02
Documents
13
Period of Report
2024-07-02
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2419328d1_8ka.htm   iXBRL 8-K/A 24560
  Complete submission text file 0001104659-24-079255.txt   190535

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA enzn-20240702.xsd EX-101.SCH 3006
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE enzn-20240702_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE enzn-20240702_pre.xml EX-101.PRE 22353
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2419328d1_8ka_htm.xml XML 3249
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-12957 | Film No.: 241112590
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)